The NeuroMove device is designed to increase the functionality of stroke victims by teaching healthy areas of the brain to compensate for damaged areas.
The NeuroMove is “significantly more sensitive than most diagnostic equipment” as it monitors muscle movement and “selects signals from the brain indicating that the patient is attempting to move a certain muscle,” according to a press release.
The device can also be used to treat spinal cord injury patients.
Last year Zynex acquired NeuroDyne and its portfolio of neurological and neuromuscular devices for $420,000.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.